Ademi investigates Crinetics-Vertex deal valuing shares at $85 each

Scrutiny of Crinetics Pharmaceuticals' sale to Vertex Pharmaceuticals has broadened further as Kahn Swick & Foti said it is investigating the proposed $85.00-per-share cash acquisition to assess whether the consideration and the process that led to it are adequate or whether the deal undervalues the company. The announcement adds to earlier investigations disclosed by Ademi LLP and Halper Sadeh LLC into the same transaction. Halper Sadeh said its review is focused on possible violations of federal securities laws and breaches of fiduciary duty, including whether Crinetics obtained the best available price, ran a fair sale process free of conflicts, and provided all material information shareholders need to evaluate the merger. Ademi previously described the transaction as implying an equity value of about $10.0 billion, or $8.8 billion net of estimated cash acquired.